Skip to content
The Policy VaultThe Policy Vault

Zelboraf (vemurafenib tablets) — Cigna

Erdheim-Chester Disease

Initial criteria

  • Patient age ≥ 18 years
  • Patient has BRAF V600 mutation-positive disease

Approval duration

1 year